Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by PutinKhuylo1on Jan 01, 2018 3:29pm
162 Views
Post# 27257276

RE:RE:RE:RE:RE:Howard; you have some explaining to do

RE:RE:RE:RE:RE:Howard; you have some explaining to doEngcan77 - I probably know more than some because I make it a point to bother management and keep informed within allowable constraints. There's one poster here who pesters everyone with inboxes and even after many replies on a particular subject still muddles the waters with his voluminous inane posts. That's one reason why I refrain from reading or posting on SH and offering my opinion. What's the point?
I admit I'm a bit disappointed that 1067 didn't happen in 2017, but all indications point to being delayed, not dead, and I can wait a bit longer. Anyways, I always believed SGLT2 was our ticket to the big show and that is not disappointing at all. Not too many micro biotechs with the potential here imho.
Bullboard Posts